EGFR Mutations in African American Patients: What Little We Know

Article

In the last several years we have seen an explosion in the knowledge and understanding of the molecular basis of cancer behavior. The identification of EGFR mutations, and their utilization in predicting response and survival in patients with untreated advanced lung cancer, provides lung cancer oncologists with the optimism that we may truly be able to offer effective “personalized therapy” for patients with lung cancer in the near future.

Should Patients with KRAS Mutations Be Treated with Epidermal Growth Factor Receptor Inhibitors (i.e. Iressa or Tarceva)?

Article

Hi again! You can think of this as a companion piece to my last post, examining some recent (but admittedly preliminary) evidence suggesting that Iressa (gefitinib) and Tarceva (erlotinib) may not be equivalent for patients with differing types of EGFR mutations. This is a slightly different topic, but one that has been quite contentious for several years: do KRAS mutations, found in 20% or more of patients with NSCLC, identify a group of patients who are resistant to EGFR inhibitors?

Are Tarceva and Iressa Equally Effective in Patients with Epidermal Growth Factor Receptor Mutations?

Article

Hi all! I had to take a month off in July as I was forgetting what my family looked like, but am now refreshed and ready to talk (write, really) about more interesting topics in the field of lung cancer. I just returned from the World Conference on Lung Cancer in San Francisco, where Drs. West, Sanborn, and I enjoyed some great foo… I mean, learned a great deal about what is happening in the world of lung cancer.